ArticleIJU case reports2026
Pseudoprogression During Enfortumab Vedotin Plus Pembrolizumab Therapy in Muscle-Invasive Bladder Cancer Achieving Pathological Complete Response: A Case Report.
Article in IJU case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Enfortumab vedotin plus pembrolizumab has emerged as a standard first-line therapy for advanced urothelial carcinoma (UC). However, pseudoprogression during this combination remains poorly characterized. Case Presentation: A 71-year-old man with muscle-invasive bladder cancer and lymph node metastasis received enfortumab vedotin plus pembrolizumab. During treatment, imaging suggested tumor progression with new hydronephrosis. Repeat transurethral resection revealed no viable tumor. Because of persistent symptoms, robot-assisted radical cystectomy was performed. Histopathological examination demonstrated no residual tumor cells, indicating pathological complete response (ypT0N0), with prominent CD8- and CD4-positive T-cell infiltration and minimal CD20-positive B-cell infiltration. Conclusion: This case suggests that pseudoprogression may occur during enfortumab vedotin plus pembrolizumab therapy. Careful interpretation of radiological findings is essential to avoid premature treatment discontinuation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.